
Discover the latest breakthroughs in oncology, including promising therapies for breast, lung, and bladder cancers, enhancing patient outcomes and hope.

Discover the latest breakthroughs in oncology, including promising therapies for breast, lung, and bladder cancers, enhancing patient outcomes and hope.

Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion–mutated NSCLC, offering hope for patients.

Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a groundbreaking cancer therapy.

A new study reveals that pembrolizumab and bevacizumab offer a promising, less toxic treatment for recurrent ovarian cancer, especially the clear cell subtype.

Neoadjuvant darovasertib showed promising tumor shrinkage in patients with uveal melanoma.

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent patient needs.

Promising results emerge from a clinical trial combining IDE397 and sacituzumab govitecan for treating MTAP-deleted urothelial cancer, showcasing safety and efficacy.

During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte study.

BioAtla's ozuriftamab vedotin advances to phase 3 trials for HPV-positive oropharyngeal cancer, aiming for accelerated FDA approval amid rising incidence.

FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in recent trials.

ABBV-706 shows promising efficacy and manageable safety in relapsed/refractory small cell lung cancer, offering hope for heavily treated patients.

FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover its potential benefits.

The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of inoperable tumors.

Nemvaleukin alfa shows promising antitumor activity in advanced melanoma and renal cell carcinoma, with manageable safety in heavily pretreated patients.

Firmonertinib shows significant antitumor activity in EGFR PACC-mutated NSCLC, with promising results in CNS penetration and manageable safety profiles.

The FDA approves Inlexzo, a groundbreaking treatment for bladder cancer, offering hope for patients unresponsive to traditional therapies.

FDA designates olomorasib and pembrolizumab as breakthrough therapy for advanced KRAS G12C-mutant lung cancer, showing promising response rates in trials.

Ifinatamab deruxtecan shows promising antitumor activity in extensive-stage small cell lung cancer, with high response rates and durable outcomes.

FDA grants orphan drug designation to BA-101, a promising treatment for glioblastoma, aiming to improve outcomes in this challenging cancer.

Osimertinib combined with chemotherapy significantly enhances overall survival in advanced EGFR-mutated non-small cell lung cancer, according to FLAURA2 trial results.

Interim results from the CAReS trial highlight ART27.13's potential to combat cancer-related weight loss, offering hope for effective treatment in CACS.

Pirtobrutinib shows significant promise in improving progression-free survival for patients with treatment-naive CLL/SLL, challenging traditional therapies.

A study reveals that azacitidine, especially in combination with ruxolitinib, improves survival in patients with advanced myeloproliferative neoplasms.

Discover the latest breakthroughs in oncology, including FDA approvals and promising therapies that offer hope for cancer patients and clinicians alike.

Rezolute streamlines the clinical pathway for ersodetug, expediting treatment for tumor hyperinsulinism and addressing urgent patient needs.

FDA fast-tracks CER-1236, a novel immunotherapy for acute myeloid leukemia, enhancing its development and potential market entry.

A groundbreaking study shows trastuzumab pamirtecan significantly improves progression-free survival in HER2-positive breast cancer patients, marking a major oncology advancement.

Lantern Pharma advances pediatric CNS cancer treatment with FDA guidance on LP-184 trial, targeting rare tumors and enhancing therapy with spironolactone.

Guardant Health's Shield test shows promising results in colorectal cancer screening, enhancing early detection and patient access with a noninvasive blood test.

Epcoritamab shows promise for outpatient treatment of relapsed DLBCL, enhancing patient access and quality of life while managing side effects effectively.